Artesunate/mefloquine

Drug Profile

Artesunate/mefloquine

Alternative Names: Artesunate 100mg/mefloquine 200mg; Artesunate-mefloquine; ASMQ FDC; MEFLIAM PLus; Mefloquine/artesunate

Latest Information Update: 30 Mar 2015

Price : $50

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation; Oswaldo Cruz Foundation
  • Class Antimalarials; Artemisinins; Phytotherapies; Quinolines; Sesquiterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria

Most Recent Events

  • 30 Mar 2015 Launched for Falciparum malaria in Malaysia, Myanmar, Vietnam, Cambodia, Niger, Burkina Faso and Tanzania (PO) by March 2015
  • 30 Mar 2015 Registered for Falciparum malaria in Thailand (PO)
  • 30 Mar 2015 Preregistration for Falciparum malaria in Indonesia, Philippines, Papua New Guinea, Laos, Cameroon, Chad, Ivory Coast, Republic of Guinea, Senegal, Ghana, Benin, Togo, Kenya, Democratic Republic of Congo, Malawi, Congo and Mali (PO) by March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top